MilliporeSigma Expands Production Facility for Cell Culture Media
MilliporeSigma has invested $25 million to expand its cell culture media production facility in Lenexa, Kan.
MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt Germany, has invested $25 million to expand its cell culture media production facility in Lenexa, Kan. With the investment, the company intends to add 98,000 ft2 of lab space and cell culture media production capability, the company announced in a July 12, 2023 press release.
Counting its Lenexa site, the company has a total of three centers of excellence for dry powder cell culture media manufacturing. The other two centers are in Nantong, China, serving the Asia Pacific region, and Irvine, Scotland, serving Europe, the Middle East, and Africa region.
“This expansion makes Lenexa the company’s largest dry powder cell culture media facility and [c]enter of [e]xcellence in North America,” said Darren Verlenden, head of Process Solutions, Life Science, MilliporeSigma, in the press release. “Investing in the region reflects our strategy to expand and diversify our supply chain to ensure we meet current and future demand for cell culture media.”
“The new production line represents the company’s vision for our Lenexa site, as it was initially constructed for three manufacturing lines for dry powder cell culture media,” Verlenden said in the release. “The new production line is the culmination of multiple years of planning, and now we are able to offer greater flexibility and faster cell culture media manufacturing for our customers.”
Source: Merck KGaA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
